Clinical trials: Anti-coagulation Therapy
Primary Immune Thrombocytopenia (ITP)
TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)
This multicenter randomized, open-label study aim to compare the efficacy and safety of TPO-RAs combining anti-CD 20 monoclonal antibody with TPO-RAs in China pediatric ITP patients .This study will be conducted in persistent or…
- Trial name
- NCT05718856
- Testing
- TPO-RAs, TPO-RAs combining anti-CD 20 monoclonal antibody
- Where
- China
- Volunteers
- 166 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Immune Thrombocytopenia, Treatment
A Prospective, One-arm and Open Clinical Study of Obinutuzumab in the Treatment of Pediatric Primary Immune Thrombocytopenia (ITP)
To evaluate the safety and efficacy of Obinutuzumab in the treatment of pediatric primary immune thrombocytopenia in patients who have not responded adequately or relapsed after first-line glucocorticoid treatment.
- Trial name
- NCT06094881
- Testing
- Obinutuzumab Injection [Gazyva]
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Kidney Injury, ICU Patients
Validation of a Regional Citrate Anticoagulation Protocol in Critically Ill Patients on Continuous Renal Replacement Therapy
The objective of this study is to evaluate the effectiveness of a modified continuous renal replacement therapy (CRRT) protocol in maintaining electrolyte balance in adult patients with acute kidney injury (AKI) admitted to the…
- Conditions
- Acute Kidney Injury, ICU Patients, Continuous Renal Replacement Therapy (CRRT), Electrolytes
- Trial name
- CRRT (NCT07514650)
- Testing
- continuous renal replacement therapy
- Where
- Spain
- Volunteers
- 43 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Mechanical Aortic and/or Mitral Valve Replacement Operation
Patient International Normalised Ratio (INR) Self-Testing Program
The aims of the study are to prove correlation between laboratory and patient self-testing (PST) measurements, estimation of INR variability within a target therapeutic zone and frequency of hemorrhagic and/or thromboembolic…
- Trial name
- NCT00925197
- Testing
- INR self-testing program
- Volunteers
- 206 people
- Sponsor
- University Hospital, Clermont-Ferrand
Atrial Fibrillation, Stroke
A Trial of Pharmacist Management of Oral Anticoagulation THerapy in the communitY for AF
This is a prospective, single-arm, feasibility pilot study of 20 participants (aged 60 years or older, with additional stroke risk factors and 'actionable' undertreated AF) recruited from a total of 4 retail and outpatient…
- Trial name
- APOTHECARYAF (NCT04907825)
- Testing
- Oral anticoagulant
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Cedars-Sinai Medical Center
Behcet Disease, Behcet Disease and Vascular Involvement
Immunosuppressive Therapy Alone Versus Plus Oral Anticoagulation in the Treatment of VT Associated With Behcet's Disease
This study is a Phase III, multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial investigating the treatment of lower extremity venous thrombosis associated with Behçet's Disease.
- Conditions
- Behcet Disease, Behcet Disease and Vascular Involvement, Deep Venous Thromboses, Post Thrombotic Syndrome
- Trial name
- BETTER (NCT06925698)
- Testing
- Rivaroxaban plus immunosupression
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 110 people
- Sponsor
- Marmara University
Coagulation
Low Dose Supplementation to Improve Anticoagulation Control With Oral Vitamin K as an Adjuvant to Warfarin Therapy
The main objective of this study is to assess the effectiveness of low dose Vitamin K1 (200 micrograms per day) at improving anticoagulation control in unstable patients on warfarin.
- Trial name
- LOCK (NCT00794755)
- Testing
- Vitamin K1 (Phytonadione)
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Angina, Stable, Angina, Unstable
Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy
The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher…
- Conditions
- Angina, Stable, Angina, Unstable, Anticoagulants
- Trial name
- COBRA-REDUCE (NCT02594501)
- Testing
- COBRA PzF, Drug Eluting Stent
- Where
- 48 sites in United States, Belgium and 6 more
- Volunteers
- 996 people
- Sponsor
- CeloNova BioSciences, Inc.
Acquired Thrombotic Thrombocytopenic Purpura
Study to Assess Efficacy and Safety of Anti-von Willebrand Factor (vWF) Nanobody in Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
This study was a Phase II, single-blind, randomized, placebo-controlled trial to determine whether anti-vWF Nanobody is safe and effective as adjunctive treatment in patients with aTTP.
- Trial name
- TITAN (NCT01151423)
- Testing
- Caplacizumab
- Where
- 51 sites in United States, Australia and 11 more
- Volunteers
- 75 people
- Sponsor
- Ablynx, a Sanofi company
Coagulation Disorder
Patient's Knowledge on Their Anticoagulating and Anti Platelet Treatment St Joseph's Hospital)
Oral antigoagulant are used more than 60 years in thrombotic diseases. Even they are indispensable, the haemorragic risk is high.That's why it's the main reason of hospitalization for iatrogeny.The complication's reasons are…
- Trial name
- NCT03304977
- Testing
- questionnaire via smartphone
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Hemophilia A, Hemophilia B
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B
Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently…
- Trial name
- NCT03938792
- Testing
- PF-06741086
- Where
- 62 sites in United States, Bulgaria and 18 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Atrial Fibrillation (AF), Coronary Artery Disease
OPTIA-AF Trial: Rhythm-Guided Antithrombotic Strategy After AF Ablation
The OPTIA-AF trial is a prospective, multicenter randomized controlled trial designed to evaluate a rhythm-guided antithrombotic strategy in patients with atrial fibrillation (AF) who maintain durable sinus rhythm after catheter…
- Conditions
- Atrial Fibrillation (AF), Coronary Artery Disease, Drug-eluting Stent
- Trial name
- OPTIA-AF (NCT07496281)
- Testing
- Oral anticoagulation, Single antiplatelet therapy
- Where
- South Korea
- Volunteers
- 2 people
- Sponsor
- Ewha Womans University Mokdong Hospital
GastroIntestinal Bleeding, Anticoagulant-induced Bleeding
Anticoagulation After GI Bleeding Pilot Study and Registry
PANTHER-GI Pilot Study will assess the feasibility of a full-scale multicentre cohort management study evaluating the safety of a standardized strategy for resuming direct oral anticoagulants (DOACs) after major DOAC-related…
- Trial name
- PANTHER-GI (NCT05290857)
- Testing
- Restart DOAC within 7 days of clinical hemostasis after GI bleeding, Restart DOAC between 7 to 14 days of clinical hemostasis after GI bleeding
- Where
- 2 sites in Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Hospital Research Institute
Acute Kidney Injury, Acute Renal Failure
A Comparison of Dilute Versus Concentrated Heparin for CRRT Anticoagulation
Heparin is commonly used for anticoagulation of the extracorporeal circuit during continuous renal replacement therapy (CRRT) but the optimal mode of delivery has not yet been validated.
- Conditions
- Acute Kidney Injury, Acute Renal Failure, Heart Failure
- Trial name
- NCT01318811
- Testing
- Dilute unfractionated heparin, Standard concentration unfractionated heparin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Vanderbilt University
Acute Renal Failure, Dialysis; Complications
New Protocol With Diluted Citrate in Continuous Techniques
The investigators designed a monitoring and control table of a citrate treatment on a specific monitor. This is the Baxter "Prismaflex" monitor, with 8.2 software version.
- Conditions
- Acute Renal Failure, Dialysis; Complications, Citrate Poisoning
- Trial name
- NCT04062812
- Testing
- the same citrate dosification in both types
- Where
- Spain
- Volunteers
- 66 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation
Evaluation of Oral Anticoagulation With Vitamin K Antagonists - The thrombEVAL Study Programme
Since decades, oral anticoagulation (OAC) with vitamin K antagonists (VKA) is an established therapy for both prevention and treatment of thromboembolism in daily clinical routine.
- Conditions
- Anticoagulant Antagonists, Vitamin K and Other Coagulants Causing Adverse Effects in Therapeutic Use, Atrial Fibrillation, Venous Thromboembolism
- Trial name
- thrombEVAL (NCT01809015)
- Where
- Germany
- Volunteers
- 2,318 people
- Sponsor
- Johannes Gutenberg University Mainz
Ischemic Stroke
Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke
The ARCHIMEDES study (Anti-inflammatory and anti-thRombotic therapy with colCHicine and low dose rIvaroxaban for Major adverse cardiovascular Events reDuction in ischEmic Stroke) will be a randomized, double-blind, 2x2 factorial…
- Trial name
- ARCHIMEDES (NCT06396858)
- Testing
- Rivaroxaban 2.5 Mg Oral Tablet, Colchicine 0.5 MG
- Volunteers
- 4,500 people
- Sponsor
- Brazilian Clinical Research Institute
Critically Ill, Acute Kidney Injury
Comparison of Biphozyl® and Phoxilium® as a Replacement Fluid During CVVH for AKI in Adults and Their Effects on pH-, Bicarbonate-levels and Respiratory Situation
The primary objectives of the BiPhox-Trial are to demonstrate, that the use of Biphozyl® as a replacement fluid in adult critically ill acute kidney injury (AKI) patients, results in a lower rate of pH excursions and of…
- Conditions
- Critically Ill, Acute Kidney Injury, Renal Replacement Therapy, Continuous Renal Replacement Therapy
- Trial name
- NCT04071171
- Testing
- CVVH with Phoxilium® in the first 48h after randomization, CVVH with Biphozyl® in the first 48h after randomization, CVVH with Phoxilium® in the second 48h after randomization (after previous 48h with Biphozyl®)
- Where
- Austria
- Volunteers
- 88 people
- Sponsor
- Medical University Innsbruck
Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage
Anticoagulation With Enhanced Gastrointestinal Safety
This study is a pragmatic cluster randomized controlled trial to evaluate the effectiveness of a clinician-facing implementation strategy on the use of medication optimization (defined as either discontinuation of all…
- Conditions
- Upper Gastrointestinal Bleeding, Peptic Ulcer Hemorrhage, Anticoagulant-induced Bleeding
- Trial name
- AEGIS (NCT05563714)
- Testing
- Clinician Notification with Nurse Facilitation (CNNF), Wait list control
- Where
- United States
- Volunteers
- 341 people
- Sponsor
- University of Michigan
Aortic Valve Stenosis, Stroke
Dual Antiplatelet Therapy Versus Oral Anticoagulation for a Short Time to Prevent Cerebral Embolism After TAVI
The purpose of this study is to determine the incidence of major vascular events (ischemic or haemorrhagics) at the third month after initiation of the antithrombotic treatment (oral anticoagulation or dual antiplatelet therapy)…
- Trial name
- AUREA (NCT01642134)
- Testing
- aspirin+clopidogrel (Duoplavin)
- Where
- 4 sites in Spain
- Volunteers
- 124 people
- Sponsor
- Andres Iñiguez Romo, MD, PhD